Apimeds Pharmaceuticals US, Inc. (APUS) stock
Close on Nov 11, 2026Market cap $3.56MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.56M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.03
- Dividend yield
- –
- Free cash flow yield
- -374.35%
Fundamentals
- Net income
- -$58.17M
- EPS, diluted
- -$36.69
- Free cash flow
- -$13.33M
- Book value per share
- $62.13
- Diluted shares
- 2M
Trading
- Previous close
- $2.69
- Open
- $2.62
- Day's range
- $2.22 – $2.69
- Volume
- 63,967
- Average volume (20 days)
- 55,713
- 52-week range
- $1.51 – $59.70
- RSI (14 days)
- 36.0
- Volatility (1 year)
- 211.1%
- Relative volume
- 0.02×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | APUS | S&P 500 | Difference | APUS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -53.0% | -2.4% | −50.6 pts | ||
| 3 months | -49.0% | -1.2% | −47.9 pts | ||
| Year to date | -85.6% | +12.3% | −97.9 pts | ||
| 1 year | -91.2% | +12.4% | −103.6 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Apimeds Pharmaceuticals US filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Update
- Update
About Apimeds Pharmaceuticals US
Pharmaceutical Preparations
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on the development of Apitox, an intradermally administered purified honeybee venom-based biologic. The company develops therapies designed to treat inflammation and manage pain symptoms associated with knee osteoarthritis and multiple sclerosis. Operating through wholly owned subsidiaries Lokahi Therapeutics, Inc. and MindWave Innovations Inc., the business directs its offerings toward clinical patient populations suffering from chronic inflammatory and neurodegenerative joint or central nervous system disorders. Additionally, through educational initiatives such as the ai² Futures Lab, the organization collaborates with university students to evaluate therapeutic assets.
Company profile, executives and historyApimeds Pharmaceuticals US stock: common questions
What is Apimeds Pharmaceuticals US's stock price?
APUS closed at $2.36 on Nov 11, 2026, down 12.27% on the day. Over the past 52 weeks it traded between $1.51 and $59.70.
What is Apimeds Pharmaceuticals US's market cap?
Apimeds Pharmaceuticals US was worth $3.56M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is APUS's P/E ratio?
Apimeds Pharmaceuticals US lost money over the twelve months to Jun 30, 2026 (diluted EPS -$36.69), so it has no meaningful P/E ratio.
Does Apimeds Pharmaceuticals US pay a dividend?
No. Apimeds Pharmaceuticals US has not paid a cash dividend over the last twelve months.
How has APUS stock performed over the past year?
Including dividends, APUS returned -91.2% over the past year, against +12.4% for the S&P 500.
Who are Apimeds Pharmaceuticals US's competitors?
Companies most similar to Apimeds Pharmaceuticals US by business, industry and size include DWTX, MNOV, JBIO, ANL, IXHL.
See a number that looks wrong?